Earnings
Home›Earnings›Guidance›Novo Nordisk CEO defends Wegovy pill economics as shar…
Novo Nordisk CEO defends Wegovy pill economics as shares fall
Investors remain skeptical about a return to sustainable growth as lower Wegovy prices are weighing on sales and competition from Eli Lilly intensifies.
Novo Nordisk’s CEO defended the economics of its Wegovy pill, but the company’s shares fell as Wall Street questioned its path back to sustainable growth, CNBC reported.
The market reaction reflected concerns that lower prices are weighing on Wegovy sales, even as the company tries to explain how its pricing and performance could improve over time.
CNBC also highlighted that investor skepticism is growing amid intensifying competition from Eli Lilly, which is adding pressure on the category’s outlook and Novo Nordisk’s growth expectations.